Tigen: Augmented cell therapies

An artificial intelligence-based system for augmented cell & gene therapies

Started
May 1, 2023
Status
Completed
Share this project

Abstract

Tigen is a clinical-stage biotech company, founded in 2017 and based in Switzerland, with a mission to bridge the gap between academic research and commercially viable therapies, particularly in the field of T cell-based cancer treatments. The rise of hyper-personalized immunocellular therapies, such as CAR T-cell treatments, is revolutionizing the approach to hard-to-treat cancers. These therapies, tailored to individual patients, have shown remarkable potential, but come also with considerable challenges. Their production process is complex and time-sensitive, requiring specialized facilities and expertise. Additionally, limited global manufacturing capacity and high costs have led to significant disparities in access, leaving many patients without the benefits of these cutting-edge treatments. Addressing these barriers is crucial to realizing the full impact of these therapies on a global scale.

People

Collaborators

SDSC Team:
Chiara Preti
Anna Fournier

PI | Partners:

Tigen Pharma:

Antoine Maison
Florent Sierro
Charlotte Théroude
Eileen Pernot

‍

Loïs Bilat
Therese Choquette
Minh Ngoc Duong
Sérgio Ribeiro

description

Objectives

Antoine Maison, Head of Digital Innovation at Tigen, together with his team, had developed a digital-twin enabled and cloud-based data platform to streamline data collection and control processes in cell therapy production, opening new avenues for data analysis and process improvement.

Working alongside the Swiss Data Science Center, Tigen aimed to enhance the efficiency, cost-effectiveness, and accessibility of cell-based therapies through the following objectives:

  • Leveraging AI-driven models to optimize key biomanufacturing parameters in real-time to enhance production efficiency and ensure high-quality outcomes.
  • Establishing proxies for cell expansion and harvesting periods to better manage and predict manufacturing processes.
  • Developing mechanistic models that capture critical dynamics within the manufacturing process, improving the robustness and reliability of data-driven approaches.
  • Integrating patient data to further personalize and tailor the biomanufacturing process to meet individual needs.

Benefits

The integration of AI-driven models and mechanistic approaches in the biomanufacturing process enhances the likelihood of successful and timely delivery of cell therapies, with a strong emphasis on patient-centric care. This platform not only improves the success rate of manufacturing but also reduces treatment time and costs, making personalized, patient-specific therapies more widely accessible.

Graphic

Figure: Real-time forecasting of cell population using in-process parameters and previous run data, with harvest recommendation customized to experts’ knowledge and requirements.

Notes

We want to thank Tigen team, in particular Antoine Maison, Florent Sierro, Charlotte Théroude, Eileen Pernot, Loïs Bilat, Therese Choquette, Minh Ngoc Duong, and Sérgio Ribeiro, for their domain knowledge and support.

Gallery

Annexe

Additional resources

Bibliography

Publications

More projects

AICADES

In Progress
AI-supported cancer data extraction for population health monitoring and research
Academia

IICU National Data Stream

In Progress
Personalized, data-driven prediction and assessment of infection-related outcomes in Swiss intensive care units (ICUs)
Academia
Public sector

SMARTT

In Progress
Smart sampling for small-angle x-ray scattering Tensor Tomography
Academia

TGSF-DA

In Progress
Data Analysis of the Turbulence and Gravity roles in Stellar Formation
Academia

More projects

No results found.
There are no results with this criteria. Try changing your search.
No result

News

Latest news

Quand l’IA soutient l’économie du canton de Vaud, la santé et l’environnement
October 27, 2026

Quand l’IA soutient l’économie du canton de Vaud, la santé et l’environnement

Quand l’IA soutient l’économie du canton de Vaud, la santé et l’environnement

Cinq projets soutenus par le canton de Vaud et réalisés avec le Swiss Data Science Center (SDSC) livrent leurs résultats après un an de
Elevating International Geneva's Impact with AI
October 21, 2026

Elevating International Geneva's Impact with AI

Elevating International Geneva's Impact with AI

Two AI projects have been selected for funding through the 2026 Geneva AI Initiative, run by the EPFL AI Center with the SDSC.
12 Zurich SMEs join next AI Innovation Program
October 15, 2026

12 Zurich SMEs join next AI Innovation Program

12 Zurich SMEs join next AI Innovation Program

Strong results encourage further AI exploration to simplify operations and boost the competitiveness of SMEs in the Canton of Zurich.

Contact us

Would you like to explore how we can work together?

Our team of data scientists and professionals looks forward to engaging in impactful, results-driven collaborations with you.